NCT02880852 Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus Status COMPLETED Phase PHASE1
NCT02847598 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Status COMPLETED Phase PHASE2
NCT02842814 Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus Status COMPLETED Phase NA
NCT02801812 Observational Multicenter Case-control Study to Assess Nailfold Capillary Abnormalities in Systemic Lupus Erythematosus Status COMPLETED Phase N/A
NCT02769195 Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE Status COMPLETED Phase N/A
NCT02741362 Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome Status TERMINATED Phase PHASE1
NCT02725515 A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus Status COMPLETED Phase PHASE2
NCT02708095 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) Status COMPLETED Phase PHASE2
NCT02660944 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Status COMPLETED Phase PHASE2
NCT02633163 Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) Status COMPLETED Phase PHASE2
NCT02631005 Walk With Ease Program For Patients With Systemic Lupus Erythematosus Status COMPLETED Phase NA
NCT02609789 A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus Status COMPLETED Phase PHASE1
NCT02558517 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus Status UNKNOWN Phase PHASE3
NCT02554474 OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis Status COMPLETED Phase NA
NCT02554019 Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Status COMPLETED Phase PHASE2
NCT02535689 Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus Status COMPLETED Phase PHASE1
NCT02533570 Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus Status TERMINATED Phase PHASE2